"The primary catalyst today is investor anxiety around the timing and outcome of the FDA's expected decision on orforglipron, Lilly's oral GLP-1 obesity pill. Lilly submitted orforglipron for obesity approval in the U.S. and Japan, and for both obesity and type 2 diabetes in the EU, with CEO David Ricks citing the submission as a "key 2025 milestone." An April decision window has been widely discussed, and markets are pricing in meaningful uncertainty around both timing and label scope."
"Phase 3 data showed patients maintained weight loss after switching from injectable incretin therapies to the oral pill, a finding that could meaningfully expand the addressable market for patients who resist injections. Yet, the approval path still carries execution risk, and prediction markets currently assign only 22% probability to FDA approval of Lilly's retatrutide (a related obesity candidate) by the end of 2026; this reflects broader skepticism about near-term regulatory timelines across Lilly's obesity pipeline."
"The selloff reflects a convergence of pressures: mounting anticipation around an FDA decision on Lilly's oral obesity pill, fresh competitive noise from Novo Nordisk in the oral GLP-1 space, and lingering concerns about compounded tirzepatide products. None of these are new stories, but together they are weighing on a stock that had already retreated sharply from its 52-week high of $1,132.06."
Eli Lilly's stock declined 5% to $937, extending a 13% year-to-date decline. The selloff stems from multiple converging pressures: investor anxiety over the FDA's expected April decision on orforglipron, Lilly's oral GLP-1 obesity medication; intensifying competition from Novo Nordisk in the oral GLP-1 space; and ongoing concerns about compounded tirzepatide products. Lilly submitted orforglipron for obesity approval in the U.S. and Japan, and for both obesity and type 2 diabetes in the EU. Phase 3 data demonstrated patients maintained weight loss after switching from injectable therapies to the oral pill, potentially expanding the addressable market. However, prediction markets assign only 22% probability to FDA approval of Lilly's related obesity candidate retatrutide by end of 2026, reflecting broader skepticism about near-term regulatory timelines.
#eli-lilly-stock-decline #fda-obesity-pill-approval #oral-glp-1-competition #pharmaceutical-regulatory-risk #novo-nordisk-rivalry
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]